Pragma Bio (former VastBiome)

Pragma Bio (formerly VastBiome) is a biotechnology company discovering new medicines using a biology-first, AI-enabled approach that mines gut-derived small molecules for therapeutic potential. The company's proprietary PIKASO platform uses bioinformatics and AI to identify Biosynthetic Gene Clusters (BGCs) from the gut microbiome, then applies synthetic biology and medicinal chemistry to make and test novel small molecules targeting the gut-immune axis. Pragma Bio focuses on immunological disorders and applies phenotypic screening to uncover new disease-modifying pathways and de-risk efficacy early in development.